Emerging drugs for the treatment of noninfectious uveitis
Expert Opinion on Emerging Drugs, cilt.24, sa.3, ss.173-190, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 24 Sayı: 3
- Basım Tarihi: 2019
- Doi Numarası: 10.1080/14728214.2019.1663823
- Dergi Adı: Expert Opinion on Emerging Drugs
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.173-190
- Anahtar Kelimeler: Autoimmunity, biological, cytokine, corticosteroid, kinase inhibitor, small-molecular-weight-inhibitor, uveitis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Uveitis is a leading cause of visual impairment and a significant burden of blindness. Although corticosteroids and conventional immunosuppressive agents have been successfully used, these are non-specific, and their long-term use may induce significant adverse effects. Areas covered: This article discusses existing local and systemic applied treatments for ocular inflammation including corticosteroids, non-biologic, and biologic disease-modifying anti-rheumatic drugs (DMARD). Potential drugs being studied in clinical trials are introduced for both local and systemic use. Expert opinion: Treatment options for uveitis continue to expand. Still, more efforts and research are needed to better understand the mechanisms potentially leading to clinical trials.